Q-omics provides the consensus-scored DDX60L profile across patient tissues and cancer cell-line models. DDX60L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, DDX60L is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, DDX60L RNA expression shows 19,212 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, HNSC, and UVM as cancer lineages where DDX60L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX60L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX60L survival associations across molecular data types. DDX60L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX60L RNA expression–survival associations across cancer types. High DDX60L expression shows unfavorable associations in PAAD, LGG, KIRC and HNSC, but favorable associations in SKCM and READ. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for DDX60L RNA expression.
This table summarizes DDX60L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DDX60L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX60L shows lower tumor expression in LUSC and higher tumor expression in HNSC, KIRP, BLCA, KIRC and STAD. The HNSC box plot shows higher DDX60L RNA expression in tumor versus normal tissue (log2 FC = +2.436, t-test p < 0.001).
This table shows molecular features associated with DDX60L in patient tissues and cancer cell lines. In patient samples, DDX60L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DDX60L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
